Optimal prostate-specific antigen screening interval for prostate cancer

D. Kobayashi, O. Takahashi, T. Fukui, P. P. Glasziou

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: To identify the optimal interval for repeat prostate-specific antigen (PSA) testing to screen for prostate cancer in healthy adults. Patients and methods: A retrospective cohort study was conducted on 7332 healthy males without prostate cancer at baseline from 2005 to 2008. Participants underwent annual health checkups including PSA testing at the Center for Preventive Medicine in Japan. Participants with high PSA (≥4.0 ng/ml) underwent further examination for prostate cancer. A subgroup analysis was conducted age group (<50 years, ≥50 years). Results: Mean age was 50 years. Mean PSA at baseline was 1.2 ng/ml. In over 50-year group, for those with initial PSA of <1.0, 1.0-1.9, 2.0-2.9, and 3.0-3.9 ng/ml at baseline, the 3-year cumulative incidence of prostate cancer was 0%, 0.1%, 0.3%, and 5.7%, respectively. No prostate cancer was identified in those <50 years, regardless of PSA level. Conclusions: If PSA screening is recommended, males >50 years with PSA of 3.0-3.9 ng/ml at baseline should undergo rescreening at 2 years. For men with PSA <3.0 ng/ml, PSA rescreening at intervals of ≥3 years is appropriate. PSA screening may not be indicated in males of <50 years of age.

Original languageEnglish
Pages (from-to)1250-1253
Number of pages4
JournalAnnals of Oncology
Volume23
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Preventive Medicine
Japan
Cohort Studies
Retrospective Studies
Age Groups
Health

Cite this

Kobayashi, D. ; Takahashi, O. ; Fukui, T. ; Glasziou, P. P. / Optimal prostate-specific antigen screening interval for prostate cancer. In: Annals of Oncology. 2012 ; Vol. 23, No. 5. pp. 1250-1253.
@article{f37289cc9f374cf88d5856245cc16eff,
title = "Optimal prostate-specific antigen screening interval for prostate cancer",
abstract = "Background: To identify the optimal interval for repeat prostate-specific antigen (PSA) testing to screen for prostate cancer in healthy adults. Patients and methods: A retrospective cohort study was conducted on 7332 healthy males without prostate cancer at baseline from 2005 to 2008. Participants underwent annual health checkups including PSA testing at the Center for Preventive Medicine in Japan. Participants with high PSA (≥4.0 ng/ml) underwent further examination for prostate cancer. A subgroup analysis was conducted age group (<50 years, ≥50 years). Results: Mean age was 50 years. Mean PSA at baseline was 1.2 ng/ml. In over 50-year group, for those with initial PSA of <1.0, 1.0-1.9, 2.0-2.9, and 3.0-3.9 ng/ml at baseline, the 3-year cumulative incidence of prostate cancer was 0{\%}, 0.1{\%}, 0.3{\%}, and 5.7{\%}, respectively. No prostate cancer was identified in those <50 years, regardless of PSA level. Conclusions: If PSA screening is recommended, males >50 years with PSA of 3.0-3.9 ng/ml at baseline should undergo rescreening at 2 years. For men with PSA <3.0 ng/ml, PSA rescreening at intervals of ≥3 years is appropriate. PSA screening may not be indicated in males of <50 years of age.",
author = "D. Kobayashi and O. Takahashi and T. Fukui and Glasziou, {P. P.}",
year = "2012",
month = "5",
doi = "10.1093/annonc/mdr413",
language = "English",
volume = "23",
pages = "1250--1253",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

Optimal prostate-specific antigen screening interval for prostate cancer. / Kobayashi, D.; Takahashi, O.; Fukui, T.; Glasziou, P. P.

In: Annals of Oncology, Vol. 23, No. 5, 05.2012, p. 1250-1253.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Optimal prostate-specific antigen screening interval for prostate cancer

AU - Kobayashi, D.

AU - Takahashi, O.

AU - Fukui, T.

AU - Glasziou, P. P.

PY - 2012/5

Y1 - 2012/5

N2 - Background: To identify the optimal interval for repeat prostate-specific antigen (PSA) testing to screen for prostate cancer in healthy adults. Patients and methods: A retrospective cohort study was conducted on 7332 healthy males without prostate cancer at baseline from 2005 to 2008. Participants underwent annual health checkups including PSA testing at the Center for Preventive Medicine in Japan. Participants with high PSA (≥4.0 ng/ml) underwent further examination for prostate cancer. A subgroup analysis was conducted age group (<50 years, ≥50 years). Results: Mean age was 50 years. Mean PSA at baseline was 1.2 ng/ml. In over 50-year group, for those with initial PSA of <1.0, 1.0-1.9, 2.0-2.9, and 3.0-3.9 ng/ml at baseline, the 3-year cumulative incidence of prostate cancer was 0%, 0.1%, 0.3%, and 5.7%, respectively. No prostate cancer was identified in those <50 years, regardless of PSA level. Conclusions: If PSA screening is recommended, males >50 years with PSA of 3.0-3.9 ng/ml at baseline should undergo rescreening at 2 years. For men with PSA <3.0 ng/ml, PSA rescreening at intervals of ≥3 years is appropriate. PSA screening may not be indicated in males of <50 years of age.

AB - Background: To identify the optimal interval for repeat prostate-specific antigen (PSA) testing to screen for prostate cancer in healthy adults. Patients and methods: A retrospective cohort study was conducted on 7332 healthy males without prostate cancer at baseline from 2005 to 2008. Participants underwent annual health checkups including PSA testing at the Center for Preventive Medicine in Japan. Participants with high PSA (≥4.0 ng/ml) underwent further examination for prostate cancer. A subgroup analysis was conducted age group (<50 years, ≥50 years). Results: Mean age was 50 years. Mean PSA at baseline was 1.2 ng/ml. In over 50-year group, for those with initial PSA of <1.0, 1.0-1.9, 2.0-2.9, and 3.0-3.9 ng/ml at baseline, the 3-year cumulative incidence of prostate cancer was 0%, 0.1%, 0.3%, and 5.7%, respectively. No prostate cancer was identified in those <50 years, regardless of PSA level. Conclusions: If PSA screening is recommended, males >50 years with PSA of 3.0-3.9 ng/ml at baseline should undergo rescreening at 2 years. For men with PSA <3.0 ng/ml, PSA rescreening at intervals of ≥3 years is appropriate. PSA screening may not be indicated in males of <50 years of age.

UR - http://www.scopus.com/inward/record.url?scp=84860447624&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr413

DO - 10.1093/annonc/mdr413

M3 - Article

VL - 23

SP - 1250

EP - 1253

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -